EXACT THERAPEUTICS EXACT Therapeutics AS AwardedNOK 7.4 M Grant for the Development of its Next Generation Ultrasound Transducer and Navigation System for ACT®OSLO /LONDON :21 December 2021 :EXACT Therapeutics AS ("EXACT-Tx" or "the Company", Euronext Growth: EXTX), a clinical-stage precision health company developing the Acoustic Cluster Therapy (ACT®), a proprietary ultrasound-mediated drug delivery platform to enhance the efficacy of therapies across multiple diseases, today announces the award of a research and innovation grant from theNorwegian Research Council (NRC) ofNOK 7.4 million for its research-based project "Ultrasound Transducer for Acoustic Cluster Therapy." The funding will support the Company's work with its partnerGE Healthcare for the development of a next-generation, bespoke, dual-frequency transducer (ultrasound probe) and a precision navigation system to help guide the ACT® procedure for targeted drug delivery in patients to allow real-time monitoring by medical professionals in the clinical setting. Dr Masha Strømme, Executive Chair of the Board, commented: "We are delighted to receive this recognition from theNorwegian Research Council , which is a testament to EXACT-Tx's innovative approach to therapeutic enhancement. The development of the navigation system and dual-frequency probe will enhance the ease of use of ACT® which will help its deployment across indications and, in combination with, a wide range of therapeutic agents. This funding will accelerate our journey towards becoming a leading precision health company." ENDS For more information, please contact:Dominic Moreland EXACT Therapeutics Email: dominic@exact-tx.comOptimum Strategic Communications Hollie Vile /Manel Mateus /Vici Rabbetts Tel: +44 (0) 208 078 4357 Email: Exact@optimumcomms.com About EXACT-Tx EXACT-Tx is a clinical-stage Norwegian precision health company developing a technology platform for targeted therapeutic enhancement - Acoustic Cluster Therapy (ACT®). ACT® follows a unique approach to ultrasound-mediated, targeted drug enhancement - with the potential to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within oncology (chemotherapy, immunotherapy), infectious diseases, and brain diseases. www.exact-tx.com About ACT® o ACT® is a proprietary formulation consisting of microbubbles and microdroplets that are activated through the application of ultrasound with the consequent increase in targeted delivery of a co-administered therapeutic agent. o ACT® is supported by a strong and broad preclinical package demonstrating therapeutic enhancement in multiple oncology models (pancreatic, breast, colon, prostate) as well as blood-brain barrier penetration. o Initial focus of the Company is oncology, however the ACT® platform has potential across therapeutic areas (infectious diseases, CNS, immunotherapy) and product classes. Forward looking statements This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the Company's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by this forward-looking statement.
Click here for more information
© Oslo Bors ASA, source
